score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61R	0.4293	410.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				NRAS p.Q61R (Missense)	1.0	MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Putatively Actionable	Inferential		Clinical evidence	Copy Number	CCND1	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CCND1 amplification was observed in a study of 109 microdissected pancreatic adenocarcinoma tumors, and is predicted to have antitumor effects in response to palbociclib.	Witkiewicz AK, Mcmillan EA, Balaji U, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.	https://doi.org/10.1038/ncomms7744								Putatively Actionable	0.0	CCND1 amplification showed reduced recurrence-free survival in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				CCND1 Amplification	1.0	MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Putatively Actionable			Guideline	Copy Number	TP53	Deletion				0.0	0.0																Putatively Actionable	0.0	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				TP53 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.P527L	0.2932	133.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				EZH2 p.P527L (Missense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Investigate Actionability	FDA-Approved		Guideline	Somatic Variant	EZH2	Missense	p.N366S	0.21600000000000003	514.0	0.0	0.0		Investigate Actionability	Tazemetostat	EZH2 inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat, an EZH2 inhibitor, for adult patients with relapsed or refactory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.	Epizyme, Inc. Tazverik (tazemetostat) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf. Revised June 2020. Accessed November 4th, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213400s000lbl.pdf								Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				EZH2 p.N366S (Missense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat74		
Investigate Actionability	Preclinical	Preclinical		Somatic Variant	ALK	Missense	p.M1615I	0.4352	108.0	8e-06	0.0		Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846	Investigate Actionability	Ceritinib	ALK inhibition	Targeted therapy	Ceritinib (LDK378), an ALK TKI, was evaluated in the context of crizotinib resistant ALK rearrangement positive non-small cell lung cancers. It was found that Certinib potently overcame crizotinib-resistant mutations. In particular, L1196M, G1269A, I1171T, S1206Y but it was not able to overcome G1202R and F1174C.	Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662-673.	https://doi.org/10.1158/2159-8290.CD-13-0846						0				ALK p.M1615I (Missense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Investigate Actionability	Preclinical			Somatic Variant	MPL	Missense	p.S268F	0.5846	65.0	0.0	0.0		Investigate Actionability	EXEL-8232	JAK2 inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to JAK2 inhibition. This variant was observed to suggest sensitivity to EXEL-8232 in vivo.	Wernig G, Kharas MG, Mullally A, et al. EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L. Leukemia. 2012;26(4):720-7.	https://doi.org/10.1038/leu.2011.261													0				MPL p.S268F (Missense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Nonsense	p.R213*	0.6944	36.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Mutations in TP53 correlated with shorter overall survival (OS) in myelodysplastic syndromes.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed April 30, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.R213* (Nonsense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.P563L	0.375	168.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				SETBP1 p.P563L (Missense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Investigate Actionability	FDA-Approved		Inferential	Somatic Variant	CHEK2	Missense	p.A17V	0.5419	179.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf								Investigate Actionability	1.0	Somatic homologous recombination mutations were predictive of platinum sensitivity compared with cases without homologous recombination mutations in Ovarian, Fallopian Tube, and Peritoneal Carcinomas.	Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764-75.	https://doi.org/10.1158/1078-0432.CCR-13-2287	0				CHEK2 p.A17V (Missense)	0.0	MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Investigate Actionability	Preclinical			Copy Number	FGFR1	Deletion				0.0	0.0		Investigate Actionability	Infigratinib	FGFR inhibition	Targeted therapy	A study of 32 Cancer Cell Line Encyclopedia cell lines demonstrating FGFR1 and FGFR2 amplification demonstrated sensitivity to Infigratinib.	Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):1118-33.	https://doi.org/10.1158/2159-8290.CD-12-0210													0				FGFR1 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Investigate Actionability			Clinical evidence	Copy Number	PAK1	Deletion				0.0	0.0																Investigate Actionability	0.0	PAK1 amplification showed reduced recurrence-free survival and decreased benefit from Tamoxifen in a randomized control trial of postmenopausal breast cancer patients.	"Bostner, Josefine, et al. ""Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer."" Oncogene 26.49 (2007): 6997-7005."	https://doi.org/10.1038/sj.onc.1210506	0				PAK1 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Somatic Variant	ROS1	Missense	p.D1854N	0.4327	104.0	0.0	0.0																					0				ROS1 p.D1854N (Missense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Biologically Relevant				Somatic Variant	FLI1	Missense	p.A125T	0.7826	23.0	0.0	0.0																					0				FLI1 p.A125T (Missense)		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	MEL-IPI_Pat74-Normal-SM-4NFW6
Biologically Relevant				Copy Number	TSC1	Deletion				0.0	0.0																					0				TSC1 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Copy Number	PRPF8	Deletion				0.0	0.0																					0				PRPF8 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Copy Number	FLCN	Deletion				0.0	0.0																					0				FLCN Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Copy Number	TACC3	Deletion				0.0	0.0																					0				TACC3 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Copy Number	FGFR3	Deletion				0.0	0.0																					0				FGFR3 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Copy Number	TSC2	Deletion				0.0	0.0																					0				TSC2 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Copy Number	FLI1	Deletion				0.0	0.0																					0				FLI1 Deletion		MEL-IPI_Pat74	MEL-IPI_Pat74-Tumor-SM-4DK2Z	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion), MSH3 p.51_51A>AAAA (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion), MSH3 p.51_51A>AAAA (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		MEL-IPI_Pat74		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.772																									0				COSMIC Signature (version 2) 7 (77%)		MEL-IPI_Pat74		
